2,934 BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Sold by State of Wyoming

State of Wyoming lessened its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 33.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,764 shares of the company’s stock after selling 2,934 shares during the period. BeOne Medicines accounts for about 0.2% of State of Wyoming’s portfolio, making the stock its 26th largest position. State of Wyoming’s holdings in BeOne Medicines were worth $2,109,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in BeOne Medicines by 24.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,541 shares of the company’s stock valued at $2,389,000 after purchasing an additional 1,284 shares in the last quarter. Park Avenue Securities LLC bought a new position in shares of BeOne Medicines during the 3rd quarter worth about $206,000. Kingswood Wealth Advisors LLC bought a new position in shares of BeOne Medicines during the 3rd quarter worth about $205,000. Signaturefd LLC grew its stake in shares of BeOne Medicines by 13.4% in the 3rd quarter. Signaturefd LLC now owns 414 shares of the company’s stock valued at $152,000 after buying an additional 49 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in shares of BeOne Medicines by 1.3% in the 3rd quarter. Quadrant Capital Group LLC now owns 4,706 shares of the company’s stock valued at $1,643,000 after buying an additional 59 shares during the period. 48.55% of the stock is owned by institutional investors.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, insider Titus B. Ball sold 132 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total transaction of $46,973.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 54,892 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the sale, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at $86,222,105.45. This represents a 18.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 377,530 shares of company stock worth $135,209,959 over the last 90 days. Corporate insiders own 6.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Barclays lifted their price target on shares of BeOne Medicines from $407.00 to $415.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Morgan Stanley restated an “overweight” rating and set a $425.00 price objective on shares of BeOne Medicines in a report on Friday, October 16th. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Guggenheim upped their target price on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $412.26.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $370.33 on Friday. The company has a market capitalization of $40.66 billion, a P/E ratio of 65.20 and a beta of 0.61. The company’s 50-day moving average is $363.15 and its 200 day moving average is $325.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $388.66.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. The business had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 earnings per share for the current year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.